Example: barber
INTEGRATED ANNUAL REPORT - UCB
• Our Phase 3b study BE RADIANT, comparing bimekizumab to secukinumab for the treatment of adults with modera-te-to-severe plaque psoriasis met its primary and all secon-dary end points, showing superiority to secukinumab. • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) accepted marketing application
Tags:
Information
Domain:
Source:
Link to this page: